Lev Pharmaceuticals News
Most Popular Lev Pharmaceuticals Story
ViroPharma to buy Lev for $442M
ViroPharma has forged a deal to buy Lev Pharmaceuticals - a developer focused on developing inflammatory therapies -- for $442 million. The deal provides ViroPharma with Lev's Cinryze program, a Read more...
Latest Headlines
- October 13, 2008
- July 15, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
